Tapan M. Kadia
University of Texas MD Anderson Cancer Center
1035 Papers
2.3K Citations
Tapan M. Kadia is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 52, co-authored 700 publications. Previous affiliations of Tapan M. Kadia include University of Perugia & University of Texas Health Science Center at Houston.
Chat about Author
Papers
Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.
Arthur E. Frankel,Marina Konopleva,Donna E. Hogge,David A. Rizzieri,Christopher L. Brooks,Thomas P. Cirrito,Steven M. Kornblau,Gautam Borthakur,Carol Bivins,Guillermo Garcia-Manero,Farhad Ravandi,Tapan M. Kadia,Michael Andreeff,Jorge E. Cortes,Kenneth Hoberman,Michael Szarek,Ivan Bergstein,Hagop M. Kantarjian,Eric K. Rowinsky +18 more
TL;DR: A single cycle of SL-401 demonstrated single agent activity in relapsed or refractory AML paties, and the maximum tolerated dose (MTD) and antitumor activity were evaluated.
31
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
Tapan M. Kadia,Xavier Thomas,Anna Dmoszynska,Agnieszka Wierzbowska,Mark D. Minden,Christopher Arthur,Jacques Delaunay,Farhad Ravandi,Hagop M. Kantarjian +8 more
TL;DR: Hypomethylating agents such 5-azacytidine (AZA) and decitabine (DAC) have been used as “lower-intensity” therapy in older patients with AML and may be associated with outcomes similar to intensive therapy.
31
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
Alireza Eghtedar,Ildefonso Rodriguez,Hagop M. Kantarjian,Susan O'Brien,Naval Daver,Guillermo Garcia-Manero,Alessandra Ferrajoli,Tapan M. Kadia,Sherry Pierce,Jorge E. Cortes,Farhad Ravandi +10 more
TL;DR: Treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers adjusted for unit time of exposure.
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
Talha Badar,Aditya Shetty,Carlos E. Bueso-Ramos,Jorge E. Cortes,Marina Konopleva,Gautam Borthakur,Sherry Pierce,Xuelin Huang,Hsiang Chun Chen,Tapan M. Kadia,Naval Daver,Courtney D. DiNardo,Susan O'Brien,Guillermo Garcia-Manero,Hagop M. Kantarjian,Farhad Ravandi +15 more
TL;DR: In this paper, the impact of bone marrow necrosis (BMN) on clinical outcome in a relatively large cohort of patients with acute leukemias was investigated. But, the BMN was associated with inferior response and poor prognosis.
30